| Master Investor Magazine
|
The price of shares in AIM-listed cell-based therapeutics specialist ReNeuron (LON:RENE) has risen by 6.87% to 136.80p (as of 10:00 GMT) after the company published interim results for the six months to 30th September. Positive data is continuing to come out of its ongoing clinical trials and the company’s loss has been substantially reduced.
CEO Olav Hellebø commented: “The period under review has been marked by significant progress across our various clinical and research programmes. During the period, and subsequent to it, we presented very encouraging positive efficacy data from the Phase 2a patients in the ongoing US Phase 1/2a clinical trial of our hRPC cell therapy candidate in retinitis pigmentosa. We have taken advantage of these early results to amend our clinical development strategy with the aim of shortening the overall time to market approval application for this therapeutic candidate.
“During the period, we have instigated a number of protocol amendments and other initiatives to accelerate patient recruitment into the ongoing US Phase 2b clinical trial of our CTX cell therapy candidate in chronic stroke disability. These amendments will result in a greatly increased number of CTX-treated patients in the study. Additionally, we have been very encouraged to see the potential of our exosome and iPS cell technologies emerge further during the period.
“We are pleased to be working with Fosun Pharma as our partner for China, following the signing of the exclusive licence agreement for both our CTX and hRPC programmes in that territory during the period. We hope to be able to announce further deals with commercial third parties across our various programmes in the months ahead“.